perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.11.06.24316481;](https://doi.org/10.1101/2024.11.06.24316481) this version posted November 7, 2024. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted

It is made available under a CC-BY 4.0 International license

Evaluating metabolome-wide causal effects on risk for psychiatric and neurodegenerative disorders

- 3 Lachlan Gilchrist^{1,2}, Julian Mutz¹, Pirro Hysi^{3,4,5}, Cristina Legido-Quigley^{6,7}, Sulev
- 4 Koks^{8,2}, Cathryn M. Lewis^{1,9,*} and Petroula Proitsi^{10,11,*}
-

perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.11.06.24316481;](https://doi.org/10.1101/2024.11.06.24316481) this version posted November 7, 2024. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

Abstract

 Evidence indicates phenotypic and biological overlap between psychiatric and neurodegenerative disorders. Further identification of underlying mutual and unique biological mechanisms may yield novel multi-disorder and disorder-specific therapeutic targets. The metabolome represents an important domain for target identification as metabolites play critical roles in modulating a diverse range of biological processes. Here, we used Mendelian 47 randomisation (MR) to test the causal effects of \sim 1000 plasma metabolites and \sim 300 metabolite ratios on anxiety, bipolar disorder, depression, schizophrenia, amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease and multiple sclerosis. In total, 85 causal effects involving 77 unique metabolites passed FDR correction and robust sensitivity analyses 51 (IVW-MR OR range: 0.73 -1.48; p_{FDR} < 0.05). No evidence of reverse causality was identified. Multivariate analyses implicated sphingolipid metabolism in psychiatric disorder risk and carnitine derivatives in risk for amyotrophic lateral sclerosis and multiple sclerosis. However, polygenic risk scores for prioritised metabolites showed limited prediction in the UK Biobank. Downstream colocalisation in regions containing influential variants identified greater than 56 suggestive evidence (PP.H₄ \geq 0.6) for a shared causal variant for 29 metabolite/psychiatric disorder trait-pairs on chromosome 11 at the *FADS* gene cluster. Most of these metabolites were lipids containing linoleic or arachidonic acid. Additional colocalisation was identified between the ratio of histidine-to-glutamine, glutamine, Alzheimer's disease and *SPRYD4* gene expression on chromosome 12. Although no single metabolite had a causal effect on a psychiatric and a neurodegenerative disease, results suggest a broad effect of lipids across brain disorders. Metabolites identified here may help inform future targeted interventions.

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) . perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.11.06.24316481;](https://doi.org/10.1101/2024.11.06.24316481) this version posted November 7, 2024. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted

63 1. Introduction

 64 Psychiatric disorders show substantial co-morbidity¹ and shared genetic 65 architecture². Additionally, they are common both prior to and within 66 neurodegenerative diseases $3-7$ – themselves genetically related $8,9$ – and are indicated 67 as risk factors for their later onset^{10–12}. Genomic analyses suggest that psychiatric and 68 neurodegenerative risk are partially underpinned by shared risk loci and causal brain 69 transcripts and proteins¹³⁻¹⁷. By further investigating shared biological risk 70 mechanisms, novel interventions may be identified with effectiveness for specific or 71 multiple disorders.

72 Metabolomics – the study of small molecules linked to metabolism – is a 73 promising tool for such investigation as it represents the stage of the omics cascade 74 closest to the phenotype¹⁸. Importantly, metabolites are strong drug target 75 candidates as many are obtained dietarily and modulate diverse biological 76 processes including gene expression. RNA metabolism and protein activity^{19–21}. 77 Obtaining samples is minimally invasive as thousands of metabolites can be detected 78 in plasma, serum or urine²².

79 Similar metabolite groups, such as ceramides, are indicated to play a role in 80 both psychiatric and neurodegenerative disorders $23-27$. However, observational 81 studies may be confounded by reverse causation²⁸. Importantly for psychiatric and 82 neurodegenerative disorders, the metabolome can be perturbed by disease 83 bathology and/or pharmaceutical interventions^{29–33}. As such, following onset and 84 treatment discerning the direction of effect and identifying causal metabolite targets 85 is challenging. These limitations can be addressed using Mendelian randomisation 86 (MR), a statistical framework that leverages genetic variants as instrumental variables 87 (IVs) to proxy an exposure and infer its causal effect on an outcome of interest³⁴. As 88 risk alleles are randomly assorted and fixed from conception, MR is less vulnerable 89 to reverse causality than classical epidemiological approaches^{28,35}. Beneficially, this 90 approach can be performed using summary statistics from large genome-wide 91 association studies (GWAS) (two-sample MR (2SMR)), allowing researchers to 92 berform increasingly powerful analyses³⁶. This approach applied to the metabolome 93 has already identified several causal risk metabolites for Alzheimer's disease, bipolar 94 disorder, major depressive disorder, and multiple sclerosis $37-41$.

 However, no study has yet been conducted to identify shared and unique metabolomic risk factors across the psychiatric and neurogenerative disorder spectrum. In this study, we assess the causal effect of ~1000 unique plasma metabolites and ~300 metabolite ratios on four psychiatric disorders (anxiety, bipolar disorder, depression and schizophrenia) and four neurodegenerative diseases (amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), Parkinson's disease

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) . perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.11.06.24316481;](https://doi.org/10.1101/2024.11.06.24316481) this version posted November 7, 2024. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted

 (PD) and multiple sclerosis (MS)). We further prioritise key metabolites using Bayesian model averaging, identify regions of shared causal variants with statistical colocalisation – integrating expression quantitative trait loci (eQTLs) – and assess the predictive performance of polygenic scores for risk metabolites on incident diseases in the UK Biobank (UKB).

106 2. Methods

107 An overview of the analyses is shown in Figure 1.

108

- 109 Figure 1: Analysis flowchart. In the Mendelian randomisation section, the three key assumptions are 110 illustrated and can be described as: (1) Instruments must be robustly associated with the exposure –
- 111 usually defined as genome-wide statistical significance of the variants; (2) Instruments are not
- 112 associated with a confounder and (3) Instruments are not associated with the outcome via pathways
- 113 other than through the exposure, for example through horizontal pleiotropy. These assumptions are
- 114 known as the (1) relevance, (2) independence and (3) exclusion restriction assumption, respectively.
- 115 ANX = anxiety; ALS = amyotrophic lateral sclerosis; AD = Alzheimer's disase; BP = bipolar disorder;
- 116 DEP = depression; MS = multiple sclerosis; PD = Parkinson's disease; SCZ = schizophrenia
- 117

118 2.1 GWAS summary statistics

119 2.1.1 Neuropsychiatric disorders

120 An overview of the GWAS summary statistics is shown in Table 1. These consisted of 121 individuals of European ancestry only. For each disorder, we performed inverse 122 variance weighted (IVW) genome-wide meta-analysis across samples $9,42-51$ using 123 METAL⁵² to maximise sample size and statistical power. Details on each sample can 124 been seen in the original papers. For AD, we used summary statistics that did not 125 contain family history-based proxy phenotyping from the UK Biobank given its noted 126 influence on the effect direction of downstream analyses⁵³. The $APOE$ region 127 (chr19:45,020,859–45,844,508 (GRCh37)) was excluded from the AD GWAS due to 128 known pleiotropic effects on relevant non-AD diseases such as heart disease and 129 bypercholesterolaemia⁵⁴. It was not meta-analysed with FinnGen freeze 9 as with the 130 others as the sample already contained samples from a previous FinnGen freeze. 131 Genetic correlations between these disorders – calculated using Linkage 132 Disequilibrium Score Regression (LDSC)⁵⁵ in GenomicSEM⁵⁶ v.0.0.5 – are described 133 and plotted in Supplementary Material 1 and 2, respectively. Full output tables are 134 in Supplementary Tables 1 and 2. Effective sample sizes were calculated as per 135 Grotzinger et al.⁵⁷, providing comparable sample size estimates representing 136 equivalently powered GWAS with a 1:1 case/control ratio.

138 Table 1: Previously conducted genome-wide association study summary statistics for psychiatric and 139 neurodegenerative disorders used in this study.

140

141 2.1.2 Plasma metabolites

 We obtained metabolite summary statistics from two studies conducted in non- overlapping samples: (1) 1,091 individual metabolites and 309 metabolite ratios measured in 8,299 unrelated individuals from the Canadian Longitudinal Study of 145 Aging (CLSA)⁵⁸ and (2) 722 individual metabolites measured in 8,809 individuals in 146 the NIHR UK Bioresource cohort⁵⁹. In both studies, metabolites were detected and quantified in plasma by Metabolon Inc. using ultra-high performance liquid chromatography-tandem mass spectroscopy. Unidentified metabolites were excluded from analyses. We performed genome-wide meta-analysis as above for 431 metabolites when the same metabolite was available in both samples for a meta-analysed sample size of 17,038.

152

153 2.1.3 GWAS standardisation

154 Prior to meta-analysis, summary statistics were standardised with MungeSumstats 60 version in R (v.4.2.1) using dbsnp 144 and the BSgenome.Hsapiens.1000genomes.hs37d5 reference genome available through Bioconducter (v.3.1.3). Missing rsids were obtained, duplicate and multi-allelic

 variants excluded, and alleles aligned to the reference, flipping effect and frequency direction accordingly. Where necessary, MungeSumstats was used to lift over genome build coordinates from GRCh38 to GRCh37 via the UCSC Genome Browser chain file.

2.2 Mendelian randomisation

2.2.1. Metabolite instrument selection

 Independent instrumental variables (IVs) were initially selected at genome-wide 166 significance ($p \le 5 \times 10^{-8}$), clumping at an r² threshold of 0.001 within 10,000 kb of the lead variants. Clumping was conducted using the ieugwasr package (v.0.1.4), PLINK 168 (v.1.9)⁶¹ binaries and the European sample of the 1000 Genomes phase 3 reference 169 panel⁶² ($N = 503$), restricted to minor allele frequency (MAF) > 0.01. This is the same 170 reference panel used by the MRC IEU OpenGWAS database[\(http://fileserve.mrcieu.ac.uk/ld/1kg.v3.tgz\)](http://fileserve.mrcieu.ac.uk/ld/1kg.v3.tgz).

172 Where less than five IVs were available for any given exposure, a lower p -value 173 threshold of 5×10^{-6} was used for IV selection as per previous analyses⁶⁴. If less than 174 -5 IVs were available at the 5×10^{-6} threshold, this metabolite was excluded. Where an IV was not available for the outcome, proxy IVs (i.e., variants in linkage disequilibrium 176 (LD) with the original instrument at $r^2 > 0.8$) were identified using snappy (v.1.0) [\(https://gitlab.com/richards-lab/vince.forgetta/snappy\)](https://gitlab.com/richards-lab/vince.forgetta/snappy) and same reference panel. 178 Proxies were selected using the highest r^2 value and closest genomic position. Prior to analysis, exposure and outcome were harmonised to the same effect allele, and strand ambiguous palindromic variants (MAF > 0.42) dropped. Instrument strength 181 was assessed via their F-statistic ($\beta_{\text{exposure}}^2/\text{SE}_{\text{exposure}}^2$), with weak instruments (F- statistic < 10) excluded. If less than 5 IVs remained, the metabolite was again 183 excluded. Instrument measurement error was assessed with the I_{G-X}^2 statistic (< 0.9 184 suggestive of measurement error)⁶⁵.

 Following the above steps the effects of 428 meta-analysed metabolites were tested, plus 740 and 132 metabolites from the CLSA and NIHR UK Bioresource studies, respectively, for a total of 1300 unique metabolites/metabolite ratios.

2.2.2. MR analyses

 We conducted the primary analyses using inverse variance weighted MR (IVW- \parallel MR) with multiplicative random effects as recommended⁶⁶. If the IVW-MR estimate was statistically significant after Benjamini-Hochberg false discovery rate (FDR) 193 correction⁶⁷ ($p_{FDR} \le 0.05$, corrected for total number of tests *specific to each* outcome), six sensitivity analyses were conducted to assess its robustness to violations of the pleiotropy assumption and instrument validity. We implemented methods that assume 196 a majority valid instruments (weighted median 68 ; penalised weighted median 69), 197 plurality valid instruments (constrained maximum likelihood $(cML)^{70}$; contamination 198 mixture model MR (MR-ContMix)⁷¹), and that exclude invalid outliers (MR-Lasso⁷²). 199 Additionally, we used MR-Egger⁷³, which gives consistent causal estimates even if all 200 instruments are not valid, provided pleiotropic effects are not correlated with variant-201 exposure associations. This is known as the Instrument Strength Independent of 202 Direct Effect (InSIDE) assumption and is MR-Egger-specific. To pass sensitivity 203 criteria, all sensitivity analysis point estimates needed to be directionally concordant 204 with the IVW estimate and the majority (≥ 4) statistically significant at $p \leq 0.05$. Where 205 a metabolite passed sensitivity criteria, we performed reverse IVW-MR as above with 206 the outcome as the exposure.

207 Pleiotropy was assessed using the MR-Egger intercept test (no evidence of 208 pleiotropy: $p_{Eoger-Intercept} \ge 0.05$) and heterogeneity using Cochran's Q (no evidence of 209 heterogeneity: $p_{Q-Stat} \ge 0.05$). Metabolites passing sensitivity were further inspected 210 using leave-one-out (LOO) analysis to assess whether causal estimates were driven 211 by the inclusion of a single influential variant. Metabolites that passed sensitivity 212 criteria and had no LOO outlier variant were considered polygenic metabolites and 213 are referred to as such henceforth. Those passing sensitivity but with a LOO outlier 214 variant were considered single instrument metabolites.

215

216 2.2 Further analysis of polygenic metabolites

217 2.3.1 Conditional analysis

218 Hysi et al.⁵⁹ noted that many metabolites are genetically correlated with phenotypes 219 related to body composition and educational level. To assess whether any identified 220 effects were driven in part by the genetic correlations between the metabolites and 221 these phenotypes, we performed conditional GWAS of the neuropsychiatric disorders 222 using multi-trait conditional and joint analysis (mtCOJO) 74 to remove the per-SNP 223 effects of body mass index (BMI), BMI-adjusted waist-to-hip ratio (WHR), and 224 educational attainment (EA).

225 We obtained GWAS summary statistics for BMI $(N = 806,834)$ and BMI-226 adjusted waist-to-hip ratio ($N = 697,734$) from the GIANT consortium^{75,76}. We 227 additionally obtained summary statistics for educational attainment (EA) from the EA4 228 GWAS meta-analysis, excluding 23andMe, from the Social Science Genetic 229 Association Consortium (SSGAC)⁷⁷ ($N = 765,283$).

230 IVW-MR estimates were recalculated for significant metabolite-231 neuropsychiatric disorder pairs post-mtCOJO and compared to the original 232 estimates. Forest plots were visually inspected for evidence of attenuation between 233 original and adjusted estimates.

234

235 2.3.2 Metabolite prioritisation using MR-BMA

236 Metabolites are highly genetically correlated⁵⁸. Consequently, univariate MR 237 estimates – which assume exposures are independent – may be biased by the 238 pleiotropic effects of other risk metabolites. Such issues may be addressed using MR 239 with Bayesian model averaging (MR-BMA)⁷⁸. MR-BMA is a multivariable MR 240 approach that ranks of causal effects among related exposures according to their 241 independent causal signal. Unlike conventional multivariable MR methods, MR-BMA 242 is well suited for the highly correlated nature of high-throughput exposures such as 243 metabolites⁷⁸. Instruments were selected by pooling those used in IVW-MR for all per-244 disorder statistically significant metabolites, excluding correlated instruments as 245 before $(r^2 > 0.001$, window = 10,000 kb). We use a prior probability of 0.1 and a prior 246 variance of 0.25 as previously^{78,79}. Metabolites were ranked according to their 247 marginal posterior probability (MIP), with MIP \geq 0.1 interpreted as causal. To avoid 248 multicollinearity between the exposures, we calculated a genetic correlation matrix 249 using the linkage disequilibrium score regression (LDSC)⁸⁰ function of 250 GenomicSEM⁵⁶. As per the original MR-BMA study, where point estimates ≥ 0.95 , we 251 excluded the metabolite correlated with the most other metabolites (if > one) or 252 retained only the metabolite with the most-significant IVW-MR estimate in the MR-253 BMA analysis (if only one).

254

255 2.3.2 Cross-trait polygenic score (PGS) analysis

256 To assess whether any of the polygenic metabolites prioritised in MR-BMA be used 257 for disease prediction, we calculated polygenic scores (PGS) – the weighted sum of 258 – an individual's risk alleles⁸¹ – within the reference standardised framework of the 259 GenoPred pipeline⁸² using individual level data from the UK Biobank (UKB)⁸³. Within 260 GenoPred, allele weights were calculated using MegaPRS⁸⁴, a PGS method that uses 261 the BLD-LDAK heritability model and improves prediction by incorporating 262 information on allele frequency. LD and various functional annotations. MegaPRS has 263 shown strong predictive performance compared to other PGS methods^{85,86}.

 UKB participants were excluded from analyses if they had unusual levels of 265 heterozygosity, a call missing rate $>2\%$ or discordant phenotypic and genetic sex (F_x) \lt 0.9 for males, $F_x > 0.5$ for females). Individuals were filtered for relatedness up to $3rd$ degree relatives based on KING kinship estimates (r < 0.044)⁸⁷ using GreedyRelate (v1.2.1) to remove one individual from each related pair, maximising sample size [\(https://gitlab.com/choishingwan/GreedyRelated\)](https://gitlab.com/choishingwan/GreedyRelated). Analyses were restricted to individuals of European ancestry. The final sample contained 381,564 271 individuals prior to any age-based exclusions.

 Case/control status was defined using the first occurrence data fields from the 273 UKB (Supplementary Table 3), where cases were ascertained using primary care Read v2 or Read CTV3 codes, hospital inpatient ICD-9 and ICD-10 codes, death record ICD-10 codes and medical condition codes self-reported at UKB assessment 276 centre visits. Individuals were excluded if the code had no event date or if the date 277 of event was before, the same year as or on the participants date of birth, or a date 278 in the future. Associations between metabolite-PGS and respective neuropsychiatric 279 disease was assessed using logistic regression, controlling for age, sex, genotyping batch, assessment centre and the first ten genetic principal components from the UKB. Within each model, the comparison group was restricted to individuals with no occurrence of any of the neuropsychiatric disorders. To provide age-appropriate controls for AD and PD, samples were restricted for those analyses to individuals aged ≥60 and ≥50 years, respectively. For DEP and ANX cases, individuals with an occurrence of BP or SCZ were excluded. The variance explained by each PGS was 286 assessed using Nagelkerke's pseudo-r². Sample sizes ranged from 140,154 to 356,763, depending on the disorder, with case numbers ranging from 600 (ALS) to 46,900 (DEP) (mean age range = 56.65-64.13; %male range = 46.32-49.35).

2.4 Further analysis of single instrument metabolites

2.4.1 Statistical colocalisation

 Using LOO analysis, we identified IVs that significantly attenuated the IVW-MR estimate when excluded. We extracted regions +/- 250 kb of these IVs and performed statistical colocalisation for each metabolite and the respective neuropsychiatric 295 disorder within the COLOC-reporter pipeline⁸⁸. Regions of interest were extracted and harmonised for each phenotype to contain only shared variants on the reference 297 panel. Colocalisation was performed using the *coloc.abf* function of the COLOC 298 package⁸⁹. A posterior probability of 0.8 for hypothesis four (PP.H₄) – presence of a shared causal variant between the phenotypes – was taken as evidence of 300 colocalisation (PP.H $_4 \geq 0.6$ taken as suggestive).

2.4.2 eQTL colocalisation

 For regions of colocalisation (including suggestive), we identified genes located within 10 kb of credible SNPs using Ensembl and biomaRt (v.2.54.0). For each gene, 305 we extracted *cis*-eQTLs from the whole blood eQTL summary data of the eQTLGen 306 Consortium⁹⁰ ($N = 31,684$) and performed colocalisation between the eQTLs and both phenotypes in each metabolite-neuropsychiatric disorder pair as above.

2.4.2 eQTL MR

 For genes colocalising with both the metabolite and neuropsychiatric disorder a trait- pair, we extracted independent instruments for gene expression from the eQTL 313 summary statistics ($p \le 5 \times 10^{-8}$; $r^2 \le 0.001$; window = 10,000 kb) and used IVW-MR to assess the causal effect of gene expression levels on the outcome and exposure. We examined the consistency of the gene expression causal effects using Summary-316 based Mendelian Randomisation $(SMR)^{91}$, extracting eQTL probes for the relevant 317 gene from blood-based eQTL summary datasets from Westra et al.⁹² ($N = 3.511$) and 318 Lloyd-Jones et al.⁹³ ($N = 2.765$). Heterogeneity was assessed using the 319 HEterogeneity In Dependent Instruments (HEIDI) test, with $p_{\text{HEDI}} < 0.05$ indicative of heterogeneity. This is essentially a test of colocalisation.

 Previous research has indicated that the causal effect of gene expression on a complex trait can be mediated by the effect of metabolites within a transcript-323 metabolite-trait causal triplet⁹⁴. Where gene expression levels showed a significant causal effect on both an outcome and a metabolite, we calculated the proportion 325 mediated using the product of coefficients method as per previous analyses⁹⁵. 326 Standard errors were estimated using the delta method and p -values drawn from a z-score distribution.

3. Results

3.1 Mendelian randomisation

 We conducted a total of 10,327 tests of the causal effect of the metabolites and ratios on the eight neuropsychiatric outcomes (instrument N-range: 5-27). Of these, 1695 333 tests were conducted with instruments clumped at 5×10^{-8} and 8632 with instruments 334 clumped at 5×10^{-6} . For single instruments, F-statistics ranged from 10.11 to 5625.88 (mean per-test F-statistics range: 20.77-1163.90). Analyses were thus not impacted 336 by weak instruments. Per-test I^2 _{G-X} ranged from 0.45 to 1.000. Only 94 tests (0.009%), 337 involving 13 unique metabolites, were conducted with $I²_{G-X} < 0.9$, suggestive of 338 measurement error. Only 27 tests were conducted using instruments with $I_{G-X}^2 \leq 0.8$, involving six metabolites: 2-hydroxyarachidate, 4-hydroxy-2-oxoglutaric acid, 4- vinylguaiacol sulphate, glycolithocholate, and O-cresol sulphate.

 Primary IVW-MR analyses identified 138 causal effects involving 113 unique metabolites after outcome-specific FDR correction (Supplementary Table 4; Figure 343 2a). Of these, 85 metabolite-outcome pairs passed our sensitivity criteria, involving 344 77 unique metabolites (Supplementary Table 5). All neuropsychiatric disorders had two or more metabolites with statistically significantly effects. No reverse effects were detected for these metabolite-outcome pairs after FDR-correction (Supplementary Table 6). IVW-MR odds ratios (OR) for metabolite-neuropsychiatric disorder trait348 pairs ranged from 0.73 to 1.48 (p -value range: 1.52 x 10⁻³ - 9.67 x 10⁻³¹; p_{FDR} range: 4.45×10^{-2} - 1.26 x 10⁻²⁷). However, MR-Egger intercept tests detected significant 350 pleiotropy for eight of the 85 metabolite-outcome pairs ($p_{Eager-Intercept}$ < 0.05) 351 (Supplementary Table 7). Cochran's Q heterogeneity tests detected significant 352 heterogeneity for 15 (p_{Q-Stat} < 0.05) (**Supplementary Table 8**). All metabolite-outcome 353 pairs with $p_{Eoger-Intercept}$ < 0.05 and 14 out of 15 with p_{Q-Stat} < 0.05 were identified as 354 influenced by single influential variants in the LOO analysis (Supplementary Table 355 9). Only the effect of the ratio of mannose to glycerol on depression ($p_{Q-Stat} = 0.043$) 356 was not driven by a single influential variant.

357 Excluding metabolites with effect estimates primarily influenced by single 358 variants left a total of 41 metabolite-neuropsychiatric disorder trait-pairs with 359 polygenic metabolites – all unique. Of these, 13 were identified with depression, 360 seven with MS, six with ALS, four each with AD and bipolar disorder, three with 361 schizophrenia, and two each with anxiety and PD (Figure 2b). These metabolites 362 were linked to nine broad metabolic classes (super-pathways), counting the 363 combinations of pathways of metabolite ratios as unique pathways (Figure 2b: 364 Supplementary Table 10). Over half $(N = 22)$ were lipids, and the rest amino acids 365 ($N = 10$), nucleotides ($N = 3$), peptides ($N = 1$), carbohydrates ($N = 1$) or ratios 366 involving amino acid/cofactors and vitamins $(N = 1)$, amino acid/energy $(N = 1)$ and 367 carbohydrate/lipid ($N = 1$) pathways. The remaining metabolite – glutamine conjugate 368 of C6H10O2 (2) – is considered only partially characterised.

369 These metabolites were implicated in 28 unique sub-pathways representing 370 the metabolic/biochemical subclasses related to the metabolites (Figure 2c; 371 Supplementary Table 10). The largest group of metabolites was related to 372 sphingolipid metabolism $(N = 5)$. All metabolites involved in sphingolipid metabolism 373 had effects on psychiatric disorder risk. Sphingosine 1-phosphate has a risk 374 increasing effect on bipolar disorder (OR $[95\%$ CII = 1.17 [1.06-1.28], ρ -value = 9.49 375 x 10⁻⁴, p_{FDR} = 0.03), while glycosyl-N-stearoyl-sphingosine (d18:1/18:0), 376 sphingomyelin (d18:1/24:1, d18:2/24:0) and sphingomyelin (d18:2/23:0, d18:1/23:1 377 and d17:1/24:1) has risk decreasing effects on depression (OR range: 0.93-0.96, p -378 value range: 2.38 x 10^{-4} – 9.91 x 10^{-4} ; ρ_{FDR} range: 0.02-0.04). Additionally, 379 sphingomyelin (d18:1/18:1, d18:2/18:0) has a risk decreasing effect on schizophrenia 380 (OR $[95\%$ CI] = 0.87 $[0.81$ -0.94], p-value = 1.89 x 10⁻⁴, p_{FDR} = 0.04).

383

384

385 Figure 2: (a). Volcano plots for anxiety (ANX), bipolar disorder (BP), depression (DEP), schizophrenia 386 (SCZ), Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS) and 387 Parkinson's disease (PD) showing odds ratios and -log₁₀ p-values from inverse variance weighted 388 Mendelian randomisation (IVW-MR) for all tested metabolites. (b). Forest plot of FDR statistically 389 significant metabolites associated with neuropsychiatric outcomes in IVW-MR and passing sensitivity 390 tests, with no leave-one-out (LOO) outliers (i.e., polygenic metabolites). Point estimates indicate odds 391 ratios with bars representing 95% confidence intervals (95%CI). Point estimates for each metabolite 392 are coloured according to their metabolic super-pathway. (c). Stacked histograms showing total count 393 of FDR statistically significant polygenic metabolites associated with each neuropsychiatric disorder, 394 with fill colours indicating metabolite sub-pathways. $AD = Alzheimer's$ disease; $ALS = Amytropic$ 395 Lateral Sclerosis; ANX = anxiety; BP = Bipolar Disorder; DEP = Depression; MS = Multiple Sclerosis; 396 PD = Parkinson's disease; SCZ = Schizophrenia

397

398 The strongest negative effect was observed for the amino acid leucine and PD 399 (OR [95%CI] = 0.73 [0.62-0.85], ρ = 9.64 x 10⁻⁵; ρ_{FDR} = 3.13 x 10⁻²). Isoleucine showed 400 similar effects (OR = 0.73 [0.62-0.86]; ρ = 1.65 x 10⁻⁴; ρ_{FDR} = 4.28 x 10⁻²). The strongest 401 positive effect was observed for the lipid 1-(1-enyl-oleoyl)-GPE (P-18:1) and MS (OR

402 = 1.48 [1.33-1.65]; p-value = 2.71 x 10⁻¹²; p_{FDR} = 3.42 x 10⁻⁹). The most statistically 403 significant effect was identified for the ratio of arachidonate (20:4n6) to oleate to 404 vaccenate (18:1) and anxiety (OR = 0.93 [0.93-0.95], ρ -value = 9.67 x 10⁻³¹, ρ_{FDR} = 405 1.26×10^{-27} .

406 The remaining 44 metabolite-neuropsychiatric disorder trait-pairs had 407 attenuated effects in the LOO analysis, involving 36 unique metabolites and six of the 408 neuropsychiatric outcomes (Supplementary Table 11). Most of the effects were 409 observed in relation to psychiatric disorders $(N = 40)$, primarily with BP ($N = 16$) and 410 DEP ($N = 16$). Another four were observed with ANX and three with SCZ. These 411 metabolite-psychiatric trait-pairs involved 33 unique metabolites, 25 of which were 412 lipids and one a ratio of lipid/carbohydrate. These lipids were involved in 12 unique 413 sub-pathways, the largest group of which was related to phospholipid metabolism (N 414 = 6). The remainder were amino acids $(N = 5)$, a carbohydrate $(N = 1)$ and a 415 xenobiotic ($N = 1$), involved in seven unique sub-pathways. Of those remaining, four 416 unique single instrument metabolites had a causal effect AD – two amino acids and 417 two xenobiotics – and a nucleotide showed causal effect on MS.

418 A total of 31 of the LOO associations were driven by 11 influential variants on 419 chromosome 11 within a ~500 kb window (61293499-61854782 bp). This region 420 contains the fatty acid desaturase (*FADS*) gene cluster, which is linked to the 421 regulation of fatty acid levels and their circulation⁹⁶. All metabolites influenced by 422 these variants were lipids and associated with psychiatric disorder risk ($N_{ANX} = 4$, N_{BP} 423 = 13, N_{DFP} = 12 and N_{SCZ} = 2). Between-variant LD estimates for the influential 424 instruments in this region were calculated using LDIinkR $(v.1.3)^{97}$ and ranged from 425 0.16-1, with $r^2 \geq 0.72$ for all variants except rs14570 and rs2524299 which showed a 426 maximum r² of 0.34 and 0.38, respectively (Figure 3a; Supplementary Table 12).

 We used Wald ratio tests to re-estimate the effect of single instrument metabolites on the relevant outcome using the influential instrument only. F-statistics ranged from 105.37 to 5625.88. Wald estimates were directionally consistent with 430 IVW-MR estimates and remained significant at $p \le 0.05$, although the protective effects of 4-guanidinobutanoate and mannonate on AD were only nominally 432 significant ($p = 0.04$ and 0.02, respectively) (Figure 3b; Supplementary Table 13). Regions containing influential instruments were further investigated using colocalisation.

436

437 Figure 3: (a). The r^e estimates between influential single variants on chromosome 11 alongside their 438 genomic location. (b). Recalculated Wald ratio estimates for metabolites with influential single variants using the influential variant only. Point estimates indicate odds ratios with bars representing 95% confidence intervals (95%CI). Point estimates for each metabolite are coloured according to their metabolic super-pathway. AD = Alzheimer's disease; ANX = anxiety; BP = Bipolar Disorder; DEP = Depression; MS = Multiple Sclerosis; SCZ = Schizophrenia

443

444 3.2 Further analysis of polygenic metabolites

445 3.2.1 Conditional analysis

 Conditioning neuropsychiatric outcomes on BMI, BMI-adjusted WHR or EA did not attenuate the IVW-MR effect estimates for causally associated metabolites when re- estimated (Supplementary Table 15; Supplementary Material 3). This suggests that the metabolite associations were not influenced by any correlation between the genetic instrument's effect and the effects of these traits as captured in the neuropsychiatric GWAS.

452

453 3.2.2 Metabolite prioritisation using MR-BMA

454 Prior to the per-outcome multivariate MR modelling in MR-BMA, we excluded the less

455 statistically significant of any metabolite pair correlated \geq 95% (Supplementary Table

- 456 15). As such, we excluded 5-methylthioadenosine (mta) from the AD model due to its
- 457 correlation with the glucose to sucrose ratio, 5-dodecenoate (12:1n7) from the MS

 model due to its correlation with N-formylmethionine and uridine, 2-myristoyl-GPC (14:0)* from the ALS model due to its correlation with 1-stearyl-GPC (O-18:0)* and the glutamine to alanine ratio from the DEP model due to its correlation with gamma-glutamylglutamine.

462 For AD, anxiety, MS, PD and schizophrenia, all metabolites had MIPs ≥ 0.1 , suggesting unique causal contributions to risk. For bipolar disorder, sphingosine 1- phosphate, the ratio of histidine to phosphate and the ratio of glycine to pyridoxal 465 passed the MIP threshold, with 3-hydroxy-5-cholestenoic acid just under (MIP = 0.098). However, of the 12 metabolites included for depression, only the two sphingomyelins (d18:1/24:1, d18:2/24:0 and d18:2/23:0, d18:1/23:1, d17:1/24:1) and 1-(1-enyl-palmitoyl)-2-arachidonoyl-GPC (P-16:0/20:4) passed. For ALS, only acetylcarnitine passed the MIP threshold. Acetylcarnitine had the highest overall MIP 470 of all metabolites tested (MIP = 0.893) (Supplementary Table 16).

3.2.3 Polygenic score (PGS) analysis

 No MR-BMA prioritised metabolite PGS was associated with any of their respective 474 outcomes after FDR correction for 23 tests ($\rho_{FDR} \ge 0.05$). Nominal associations were observed between depression and the PGS for sphingomyelin (d18:2/23:0, d18:1/23:1, d17:1/24:1) and 1-(1-enyl-palmitoyl)-2-arachidonoyl-GPC (P-16:0/20:4) 477 with identical effect sizes (OR[95%CI] = 0.989 [0.979-0.998], p -value range = 2.131 \times 10⁻² - 2.517 \times 10⁻²) and between the PGS for leucine and PD (OR [95%CI] = 0.962 $\,$ [0.93- 0.996, ν -value = 2.814 x 10⁻²). These effects were directionally consistent with the MR estimates but had non-relevant predictive ability given small Nagelkerke's 481 pseudo-r² estimates (Nagelkerke's pseudo-r²_{MAX} = 1.445 x 10⁻⁴) (**Supplementary** Table 17).

3.3 Further analysis of single instrument metabolites

3.3.1 Colocalisation at loci of influential instruments

 Of the 44 colocalisation tests conducted in regions +/- 250 kb of the LOO influential 487 variants, 26 showed evidence of colocalisation (PP.H₄ \geq 0.8) and a further five had 488 suggestive evidence (PP.H₄ \geq 0.6) (**Supplementary Table 18**). All except one of these regions were on chromosome 11 within a ~500 kb window (61293499-61854782 bp). All disorders colocalising with metabolites in this region were psychiatric and every psychiatric disorder examined showed colocalisation with at least one metabolite. Colocalisation has been previously observed between the omega-3 fatty acid 493 docosahexaenoic acid (DHA) and depression within the same region³⁹.

 All implicated metabolites except 1-stearoyl-2-docosapentaenoyl-GPC (18:0/22:5n6)* were complex fatty acid chains containing the fatty acids arachidonic 496 acid (AA) ($N = 18$), linoleic acid (LA) ($N = 5$), alpha-linolenic acid (ALA) ($N = 1$) or 497 both AA and LA $(N = 4)$. Higher levels of AA-containing metabolites were consistently 498 protective in Wald estimates while higher levels of LA- or ALA-containing metabolites 499 had risk increasing effects. Where ratios contained both AA- and LA-containing 500 metabolites, higher levels of the AA relative to the LA was protective and higher LA 501 metabolites relative to the AA risk increasing (Supplementary Table 19). This is 502 concordant with previous metabolome-wide MR analysis of bipolar disorder⁴¹ and 503 observational analysis of depression⁹⁸. The other region of colocalisation was 504 identified on chromosome 12 (56615338-57115338) between the ratio of histidine-to-505 glutamine and AD (PP.H $_4$ = 0.92).

506 Two tests showed evidence of two distinct causal variants at the tested locus 507 – the ratio of glucose to mannose and depression (chr2: 27480940-27980940; PP.H3 508 = 0.92) and docosapentaenoate (n6 DPA; 22:5n6) and bipolar disorder (chr11: 509 61347212-61847212; PP.H₃ = 0.99). Suggestive evidence for two distinct causal 510 variants was also identified for butyrylglycine and depression (chr12:120925524- 511 121425524; PP.H₃ = 0.70), methylsuccinate and depression (chr12:120926083-512 121426083; PP.H₃ = 0.63), and 5-methyluridine (ribothymidine) and MS 513 (Chr22:50687969-51187969; PP.H₃ = 0.63). PP.H₃ \geq 0.6 in these regions suggests 514 that MR estimated effects arose from linkage disequilibrium, violating MRs horizontal 515 pleiotropy assumption. Remaining colocalisation tests were inconclusive.

516

517 3.3.2 eQTL colocalisation

518 In total, nine genes were identified within 10 kb of credible SNPs at colocalising loci 519 (Supplementary Table 20). For the colocalisation analyses at chr11:61293499- 520 61854782, eQTLs for *MIR611* or *MIR1908* were not available in the eQTLGen 521 summary statistics. As such, follow-up eQTL colocalisation in this region was 522 conducted only with *MYRF, TMEM258, FEN1*, FADS2 and *FADS1*, For the region 523 chr12:56615338-57115338, eQTLs were not available for MIP, but were available for 524 GLS2 and SPRYD4. In total, 130 colocalisation tests were conducted with eQTLs. Of 525 these, only eQTLs for *SPRYD4* colocalised with both a risk metabolite and its 526 respective neuropsychiatric outcome: the ratio of histidine-to-glutamine (PP.H₄ = 527 0.91) and AD (PP.H₄ = 0.91). Additional colocalisation was identified for *GLS2* with 528 the ratio of histidine-to-glutamine (PP.H₄ = 0.99), but not AD (PP.H₄ = 0.42). *TMEM258* 529 colocalised with depression (PP. $H_4 = 0.86$). Suggestive colocalisation was identified 530 between $TMEM258$ and anxiety and between $MYRF$ and depression (PP.H₄ \geq 0.6). Of 531 the remaining tests, 113 indicated two distinct causal variants in the region (PP.H₃ ≥ 532 0.8), four were suggestive of only a causal variant for gene expression, and the 533 remainder inconclusive (Supplementary Table 21). 534

535 3.3.3 eQTL MR for the histidine to glutamine ratio and AD

536 We conducted MR analyses for the effect of *SPRYD4* expression levels on the ratio 537 of histidine-to-glutamine and AD using five independent instruments. SPRYD4 538 expression levels were identified as increasing risk for AD (OR = 1.08 [1.02-1.16], β 539 [95%CI] = 0.08 [0.02-0.15], ρ -value = 0.007) and the level of the ratio of histidine to 540 glutamine (β [95%Cl] = 0.30 [0.18-0.42], ρ -value = 1.16 x 10⁻⁶). SMR estimates for 541 the effect of *SPRYD4* expression were directionally consistent and statistically 542 significant at $p \le 0.05$ for AD and the ratio of histidine-to-glutamine across eQTL 543 panels. HEIDI tests did not indicate heterogeneity ($p_{HEDI} \ge 0.05$) (Supplementary 544 Table 22). There was no evidence that the ratio of histidine to glutamine substantially 545 mediates the effect of *SPRD4* expression on AD, with only a nominally significant 546 association and wide confidence intervals (proportion mediated [95%CI] = 63.20% 547 [1.80-124.59%], ρ -value = 0.043).

548

549 3.6 Further examination of histidine, glutamine, AD and SPRYD4

 To further evaluate the association between the ratio of histidine to glutamine, we re- examined the IVW-MR estimates for the separate effects of histidine and glutamine 552 on AD. No causal effect was observed for histidine on AD, not even nominally (OR = 553 1.11 [0.99-1.27], $\beta = 0.11$ [-0.011-0.24], ρ -value = 0.07). However, there was a 554 nominally significant negative causal effect for glutamine ($OR = 0.87$ [0.81-0.94], β $[95\% \text{Cl}] = -0.14 [-0.21 \text{ to } -0.06]$, ρ -value = 0.0007, $\rho_{FDR} = 0.052$). Although glutamine passed post-hoc sensitivity criteria with no evidence of pleiotropy or heterogeneity (Supplementary Table 23), LOO identified the same influential variant on chromosome 12 as observed for the ratio of histidine-to-glutamine – the 3′-UTR 559 variant rs2657879 (Supplementary Table 24). For glutamine, the effect of rs2657879 was in the opposite direction to the histidine-to-glutamine ratio.

561 A Wald ratio test using only this instrument estimated a negative effect of 562 glutamine on AD risk (OR = 0.84 [0.76-0.91], β = -0.19 [-0.28 to -0.09], ρ -value = 9.65 563 \times 10⁻⁵). Strong evidence of colocalisation was observed between glutamine and AD 564 in the region (PP.H₄ = 0.92), and between glutamine and *SPRYD4* (PP.H₄ = 0.98) 565 (Supplementary Table 25). Gene expression levels of SPRYD4 were negatively 566 associated with glutamine in the MR analysis (β = -0.35 [-0.52 to -0.18], ρ -value = 567 3.94 x 10⁻⁵). Strong, directionally consistent effects of $SPRD4$ expression on glutamine 568 were observed in SMR (Supplementary Table 26). However, the HEIDI tests 569 indicated heterogeneity ($p_{HEIDI} \leq 0.05$). There was no evidence that glutamine 570 mediated the effects of SPRD4 expression on AD (proportion mediated [95%CI] =

- 571 75.81% [-0.36-151.99%], p -value = 0.051). LocusZoom plots for the ratio of histidine
- 572 to glutamine, glutamine, AD and *SPRYD4* gene expression are shown in Figure 4. 573

574 Figure 4: LocusZoom plots of the colocalising region (PPH₄ \geq 0.8) chr12: 56615338-57115338 for 575 Alzheimer's disease, the ratio of histidine to glutamine, glutamine, and SPRYD4 expression.

4. Discussion

 We identified 77 unique plasma metabolites and a total of 85 sensitivity robust MR estimated causal effects on neuropsychiatric disorder risk. Over half of associations were driven by single influential variants. Of these, 30 metabolite-neuropsychiatric disorder trait-pairs had greater than suggestive colocalisation and 29 were lipids 581 colocalising with a psychiatric disorder near the *FADS* gene cluster on chromosome 11. No eQTL colocalisation was observed for any metabolite-outcome trait-pair in this region, suggesting the underlying mechanisms are not related to shared gene expression effects. Additional colocalisation was observed between AD glutamine-585 related metabolites and *SPRYD4* gene expression on chromosome 12. For the remaining 41 polygenic metabolites, multivariate analysis with MR-BMA prioritised 23 metabolites and implicated sphingolipids and carnitine derivatives in psychiatric and neurodegenerative risk respectively. However, the predictive performance of metabolite polygenic scores was negligible in the UK Biobank.

 Lipids – specifically polyunsaturated fatty acids (PUFAs) – have previously shown MR causal effects on depression, with docosahexaenoic acid (DHA) 592 colocalising at the FADS gene cluster³⁹. Our study highlights the broader significance of this region in linking lipid levels to risk across the psychiatric disorder spectrum. Here, we identify suggestive colocalisation between at least one lipid and every examined psychiatric disorder. Nearly all lipids colocalising with psychiatric disorders contained linoleic acid (LA) or arachidonic acid (AA) – both omega-6 PUFAs. AA-containing lipids were consistently protective, while LA-containing lipids increased risk. These findings are consistent with other MR studies of bipolar 599 disorder, depression and schizophrenia $41,99,100$. Our results suggest that these associations extend to ANX. Although these effects were primarily driven by shared causal variants on chromosome 11, several polygenic metabolites comprised of AA/LA-containing lipids also showed causal effect on psychiatric risk. The ratio of arachidonate (20:4n6)-to-oleate-to-vaccenate (18:1) and 1-(1-enyl-palmitoyl)-2- arachidonoyl-GPC (P-16:0/20:4) – both AA-containing – had risk decreasing effects on anxiety and depression respectively and were prioritised in multivariate analysis. In single instrument analyses, this ratio had risk decreasing effects on bipolar disorder, depression and schizophrenia, colocalising with all. These results suggest that effects of AA/LA-containing lipids in psychiatric risk may extend beyond effects on chromosome 11.

 Circulating levels of lipids containing LA and AA may be promising intervention targets for psychiatric disorders. LA – the most abundant omega-6 PUFA in the 612 western diet – is found in nearly all manufactured food through vegetable oils¹⁰¹, while 613 AA is found in animal products such as meat, poultry, fish and $eggs^{102}$. As free fatty acids AA is a downstream product of LA, from which it is synthesised through 615 desaturation and chain elongation¹⁰² (Supplementary Material 4).

616 Free LA and AA are linked to inflammatory dysregulation¹⁰³ – itself implicated 617 in psychiatric disorders^{104,105}. AA is catalysed by cytochrome P450 enzymes to epoxyeicosatrienoic acids (EETs), which show anti-inflammatory effects and are 619 suggested to be protective of neurological function¹⁰⁶. The deleterious effects of LA- containing lipids compared to the protective effects of AA-containing lipids may implicate dysregulated conversion from LAs to AAs, contributing to elevated inflammation as less AA is available for conversion to anti-inflammatory EETs. However, LA-to-AA conversion is relatively low in humans and requires LA to be in free form following cleavage from lipid molecules via enzymes such as phospholipase A2 (PLA2). Although PLA2 action on fatty acids has been previously 626 linked to inflammatory depression¹⁰⁷, further investigation is required to elucidate mechanisms by which LA- and AA-containing lipids contribute to psychiatric risk.

 The effects of the ratio of histidine-to-glutamine and glutamine on AD observed here are in line with previous MR evidence suggesting higher blood glutamine as 630 protective $37,108$. Interestingly, glutamine is noted to exert a neuroprotective effect 631 against β-amyloid aggregation¹⁰⁹ – a key drug target for AD¹¹⁰. This study provides further evidence for its protective effects on AD risk and suggests the association is driven by shared causal variants on chromosome 12. Further, we observe that the association between AD and glutamine may be partially driven by the mutual effect 635 of SPRYD4 gene expression. As SPRYD4 has not been previously identified in AD GWAS it represents a novel locus of interest for future study.

 Our study also provides further evidence for the role of sphingolipid metabolism in psychiatric disorders. Sphingolipids are fatty acids with roles in cell 639 growth/death, inflammation, mitochondrial function and immune response¹¹¹. We identified two sphingomyelins and glycosyl-N-stearoyl-sphingosine (d18:1/18:0) as protective for depression, with the sphingomyelins both prioritised in multivariate analysis. Further, sphingomyelin (d18:1/18:1, d18:2/18:0) was protective for schizophrenia and sphingosine-1-phosphate indicated to elevate risk of bipolar disorder. Sphingomyelins are central to ceramide metabolism, to which they are 645 converted via sphingomyelinase and back via sphingomyelin synthase¹¹² (Supplementary Material 5). Ceramides are catabolised into sphingosine and 647 eventually sphingosine-1-phosphate¹¹². General dysfunction of sphingolipid metabolism, particularly ceramide aggregation, has been previously observed in 649 psychiatric disorders^{23,24,111,112} and reduced sphingomyelin levels may contribute to 650 elevated neuroinflammation¹¹². As such, the ceramide system is a proposed pathway for drug-based interventions for psychiatric disorders¹¹². This study implicates sphingomyelins as possible protective targets.

 Although fewer metabolomic patterns were observed in neurodegenerative disorders we did observe protective effects of several carnitine related metabolites – adipoylcarnitine for MS and acetylcarnitine and propionylcarnitine for ALS. All three are metabolised from L-carnitine, which plays a role in the transportation of fatty acids 657 to mitochondria¹¹³, and when acetylated is suggested to slow disease progression for 658 both disorders and AD¹¹⁴⁻¹¹⁶. Further, lower serum carnitine levels are observed in 659 ALS¹¹⁷ and are associated with increased fatique in MS¹¹⁸. A randomised control trial (RCT) of acetylcarnitine supplementation in ALS suggests it may improve self- sufficiency in patients compared to placebo¹¹⁴. The importance of acetylcarnitine for ALS is further emphasised by our multivariate analysis, where it was the only metabolite prioritised for ALS and had the highest MIP of any metabolite examined. Interestingly, a larger phase two/three RCT of acetylcarnitine effects on biological and clinical outcomes in ALS is underway [\(https://classic.clinicaltrials.gov/ct2/show/NCT06126315\)](https://classic.clinicaltrials.gov/ct2/show/NCT06126315). The remaining polygenic metabolites did not show clear functional relatedness, indicating disorder-specific metabolomic contributions – broadly confirmed in MR-BMA, where, for most 669 disorders, all metabolites had a MIP \geq 0.1, indicating unique causal effects.

 Although no specific metabolites were identified with an effect on both a psychiatric and neurodegenerative disorder, our results suggest the general importance circulating lipids in both categories. Dietary lipids are known to modulate neuroinflammation and play an important role in the brain by regulating neuronal and 674 synaptic function¹¹⁹. Future studies exploring biological overlap in neuropsychiatric disorders may therefore wish to focus on lipidomic analysis for the purposes of further elucidating shared metabolic pathways.

 Several disorder-specific metabolites warrant further discussion. For example, we replicated the risk-increasing effect of uridine on MS previously identified observationally and in MR^{40,120}. Uridine is linked to pyrimidine metabolism with important biological functions including RNA synthesis and the regulation of glucose, 681 lipid and amino acid levels¹²¹. Interesting, within pyrimidine biosynthesis, uridine is an 682 eventual metabolic product of dihydroorotate¹²¹, also identified here as increasing risk for MS. Additionally, the branch chain amino acids (BCAAs) leucine and its isomer isoleucine were both protective for PD. Plasma levels are noted to be lower in 685 cases than controls and correlated with increased functional disability¹²². In an RCT of PD/parkinsonism, supplementation with leucine and vitamin D enriched whey protein was significantly associated with increased lower body function and muscle 688 mass retention¹²³. Our findings provide further evidence of the protective effects of leucine/isoleucine in PD and suggest them as possible interventional targets.

 In the UKB, PGS for prioritised polygenic metabolites showed limited prediction of their respective outcome disorder. Polygenic scores are noted to explain

692 only a small proportion of the variance even within the same phenotype¹²⁴. As such, it is not entirely surprising that we are unable to detect significant associations cross- trait, particularly given the smaller effective target sample size available in the UKB compared to the large, meta-analytic samples sizes available from GWAS summary statistics for use in MR. To improve prediction, future studies might aggregate the genetic effects of multiple metabolites to better capture the total underlying metabolic 698 risk for disease, for example through a multi-PGS framework¹²⁵.

 In conclusion, we performed metabolome-wide MR to test the causal effects of 1300 metabolites/metabolite ratios on eight neuropsychiatric disorders. Results implicate AA and LA-containing lipids across the psychiatric disorder spectrum, with 702 shared causal variants identified near the *FADS* gene cluster. We also identified shared causal variants between glutamine metabolites and Alzheimer's disease, and 704 identify a shared effect of *SPRD4* gene expression. Additionally, our results implicate sphingolipid metabolism in psychiatric disorders and carnitine related metabolites as protective for MS and ALS, alongside several promising target metabolites with disease-specific effects. More broadly, this study suggests that lipid metabolism plays an important role in both psychiatric and neurodegenerative risk. The metabolites identified in this study can help inform potential interventions and future, targeted studies of metabolic contributions to disease risk.

5. Limitations

 This study used data from individuals of European ancestry only and as such may 714 lack generalisability. Further, as previously noted⁷⁹, although the exclusion of the 715 APOE region from the AD analyses is necessary to avoid violating MR assumptions, 716 this may result in false negatives due to the regions known role in lipid metabolism¹²⁶. Conversely, we can have greater confidence that the metabolites identified here are 718 not confounded by APOE effects. Given the importance of this region in AD and lipid metabolism, it deserves specific focus in future metabolomic work. Further, MR requires that several assumptions – such the availability of suitable instruments and absence of pleiotropic effects – be met to provide reliable results. Although we 722 mitigate against these by including only strong instruments (F-statistic \geq 10) and using a robust sensitivity criterion to delineate causal metabolites, results should be interpreted with caution prior to further triangulation.

6. Funding and acknowledgements

727 LG is funded by the King's College London DRIVE-Health Centre for Doctoral Training and the Perron Institute for Neurological and Translational. JM is supported by the King's Prize Fellowship. This study has been partly delivered through the National Institute for Health and Care Research (NIHR) Maudsley Biomedical Research Centre (BRC). PP is funded by an Alzheimer's Research UK Senior Research Fellowship.

 This research has been conducted using the UK Biobank Resource under Application Number 82877. Ethical approval for the UK Biobank study has been granted by the National Information Governance Board for Health and Social Care and the NHS North West Multicentre Research Ethics Committee (11/NW/0382). Written informed consent was obtained from all participants by the UK Biobank. We thank the UK Biobank Team for collecting the data and making it available. We also thank the UK Biobank participants.

 We also thank and acknowledge the contribution and use of the CREATE high- performance computing cluster at King's College London (King's College London. (2022). King's Computational Research, Engineering and Technology Environment (CREATE)).

 We want to acknowledge the participants of the FinnGen study and the veterans of the Million Veterans Project, as well as the research teams for both studies.

 For the purposes of open access, the author has applied a Creative Commons 747 Attribution (CC BY) license to any Accepted Author Manuscript version arising from this submission.

7. Data availability

 Data is available on reasonable request from the UK Biobank [\(https://www.ukbiobank.ac.uk/learn-more-about-uk-biobank/contact-us\)](https://www.ukbiobank.ac.uk/learn-more-about-uk-biobank/contact-us).

 Summary statistics from FinnGen are available online [\(https://www.finngen.fi/en/access_results\)](https://www.finngen.fi/en/access_results) and from the Million Veterans Project via dbGaP request [\(https://www.ncbi.nlm.nih.gov/projects/gap/cgi-](https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?studyid=phs001672.v1.p1)[bin/study.cgi?studyid=phs001672.v1.p1\)](https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?studyid=phs001672.v1.p1).

 GWAS summary statistics from the Psychiatric Genomics Consortium (PGC) for Alzheimer's disease, anxiety, bipolar disorder, depression and schizophrenia are available from their website [\(https://pgc.unc.edu/for-researchers/download-results/\)](https://pgc.unc.edu/for-researchers/download-results/). Summary statistics for anxiety from iPSYCH are also available online [\(https://ipsych.dk/en/research/downloads\)](https://ipsych.dk/en/research/downloads). For Parkinson's disease and ALS, summary statistics are available on GWAS Catalog at <https://www.ebi.ac.uk/gwas/studies/GCST009325> and <https://www.ebi.ac.uk/gwas/studies/GCST90027164> respectively. For multiple sclerosis, summary statistics are available though the IEU Open GWAS Project [\(https://gwas.mrcieu.ac.uk/datasets/ieu-b-18/\)](https://gwas.mrcieu.ac.uk/datasets/ieu-b-18/). Summary statistics for metabolites 767 measured from Chen et al.⁵⁸ are available on GWAS catalog

- [\(https://www.ebi.ac.uk/gwas/studies/\)](https://www.ebi.ac.uk/gwas/studies/) under accession numbers GCST90199621- 90201020. Access to summary statistics for the metabolites measured by Hysi et al.⁵⁹ were made available following request to the original authors.
-

8. Conflicts of Interest

 CML is on the Scientific Advisory Board of Myriad Neuroscience and has received honoraria for consultancy from UCB. C.L.-Q. has received consultancy fees from

Pfizer. C.L.-Q. has received honoraria, travel or speakers' fees from Biogen and

research funds from Pfizer and Novo Nordisk. C.L.-Q. is the director of the company

BrainLogia. All other authors declare no competing interests.

References

- 1. Plana-Ripoll, O. *et al.* Exploring comorbidity within mental disorders among a danish national population. *JAMA Psychiatry* **76,** 259–270 (2019).
- 2. Grotzinger, A. D. *et al.* Genetic architecture of 11 major psychiatric disorders at biobehavioral, functional genomic and molecular genetic levels of analysis. *Nat. Genet.* **54,** 548–559 (2022).
- 3. Aarsland, D. *et al.* Neuropsychiatric symptoms in patients with Parkinson's disease and dementia: frequency, profile and associated care giver stress. *J. Neurol. Neurosurg. Psychiatry* **78,** 36–42 (2007).
- 4. Turner, M. R., Goldacre, R., Talbot, K. & Goldacre, M. J. Psychiatric disorders prior to amyotrophic lateral sclerosis. *Ann. Neurol.* **80,** 935–938 (2016).
- 5. Ismail, Z. *et al.* Psychosis in Alzheimer disease mechanisms, genetics and therapeutic opportunities. *Nat. Rev. Neurol.* **18,** 131–144 (2022).
- 6. Chertcoff, A. S. *et al.* Psychiatric comorbidity during the prodromal period in patients with multiple sclerosis. *Neurology* **101,** e2026–e2034 (2023).
- 7. Burchill, E. *et al.* The impact of psychiatric comorbidity on Parkinson's disease outcomes: a systematic review and meta-analysis. *Lancet Reg. Health Eur.* **39,** 100870 (2024).
- 8. Wainberg, M., Andrews, S. J. & Tripathy, S. J. Shared genetic risk loci between Alzheimer's disease and related dementias, Parkinson's disease, and amyotrophic lateral sclerosis. *Alzheimers Res. Ther.* **15,** 113 (2023).
- 9. Wightman, D. P. *et al.* The genetic overlap between Alzheimer's disease, amyotrophic lateral sclerosis, Lewy body dementia, and Parkinson's disease. *Neurobiol. Aging* **127,** 99–112 (2023).
- 10. Gimson, A., Schlosser, M., Huntley, J. D. & Marchant, N. L. Support for midlife anxiety diagnosis as an independent risk factor for dementia: a systematic review. *BMJ Open* **8,** e019399 (2018).
- 11. Kuusimäki, T. *et al.* Increased risk of parkinson's disease in patients with schizophrenia spectrum disorders. *Mov. Disord.* **36,** 1353–1361 (2021).
- 12. Richmond-Rakerd, L. S., D'Souza, S., Milne, B. J., Caspi, A. & Moffitt, T. E. Longitudinal Associations of Mental Disorders With Dementia: 30-Year Analysis of 1.7 Million New Zealand Citizens. *JAMA Psychiatry* **79,** 333–340 (2022).
- 13. Andreassen, O. A. *et al.* Genetic pleiotropy between multiple sclerosis and schizophrenia but not bipolar disorder: differential involvement of immune-related gene loci. *Mol. Psychiatry* **20,** 207–214 (2015).
- 14. McLaughlin, R. L. *et al.* Genetic correlation between amyotrophic lateral sclerosis and schizophrenia. *Nat. Commun.* **8,** 14774 (2017).
- 15. Reynolds, R. H. *et al.* Local genetic correlations exist among neurodegenerative and neuropsychiatric diseases. *npj Parkinsons Disease* **9,** 70 (2023).
- 16. Wingo, T. S. *et al.* Shared mechanisms across the major psychiatric and neurodegenerative diseases. *Nat. Commun.* **13,** 4314 (2022).
- 17. Harerimana, N. V. *et al.* Genetic evidence supporting a causal role of depression in alzheimer's disease. *Biol. Psychiatry* **92,** 25–33 (2022).
- 18. Patti, G. J., Yanes, O. & Siuzdak, G. Innovation: Metabolomics: the apogee of the omics trilogy. *Nat. Rev. Mol. Cell Biol.* **13,** 263–269 (2012).
- 19. Guijas, C., Montenegro-Burke, J. R., Warth, B., Spilker, M. E. & Siuzdak, G. Metabolomics activity screening for identifying metabolites that modulate phenotype. *Nat. Biotechnol.* **36,** 316–320 (2018).
- 20. Garana, B. B. & Graham, N. A. Metabolomics paves the way for improved drug target identification. *Mol. Syst. Biol.* **18,** e10914 (2022).
- 21. Rinschen, M. M., Ivanisevic, J., Giera, M. & Siuzdak, G. Identification of bioactive metabolites using activity metabolomics. *Nat. Rev. Mol. Cell Biol.* **20,** 353–367 (2019).
- 22. Gowda, G. A. N. *et al.* Metabolomics-based methods for early disease diagnostics. *Expert Rev Mol Diagn* **8,** 617–633 (2008).
- 23. Dinoff, A., Herrmann, N. & Lanctôt, K. L. Ceramides and depression: A systematic review. *J. Affect. Disord.* **213,** 35–43 (2017).
- 24. Brunkhorst-Kanaan, N. *et al.* Targeted lipidomics reveal derangement of ceramides in major depression and bipolar disorder. *Metab. Clin. Exp.* **95,** 65–76 (2019).
- 25. Filippatou, A. G. *et al.* Serum ceramide levels are altered in multiple sclerosis. *Mult. Scler.* **27,** 1506–1519 (2021).
- 26. Chowdhury, M. R., Jin, H. K. & Bae, J.-S. Diverse roles of ceramide in the progression and pathogenesis of alzheimer's disease. *Biomedicines* **10,** (2022).
- 27. Vos, M., Klein, C. & Hicks, A. A. Role of ceramides and sphingolipids in parkinson's disease. *J. Mol. Biol.* **435,** 168000 (2023).
- 28. Davey Smith, G. & Ebrahim, S. Epidemiology--is it time to call it a day? *Int. J. Epidemiol.* **30,** 1–11 (2001).
- 29. Webhofer, C. *et al.* Metabolite profiling of antidepressant drug action reveals novel drug targets beyond monoamine elevation. *Transl. Psychiatry* **1,** e58 (2011).
- 30. Pillinger, T. *et al.* Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. *Lancet Psychiatry* **7,** 64–77 (2020).
- 31. Shao, Y. *et al.* Comprehensive metabolic profiling of Parkinson's disease by liquid chromatography-mass spectrometry. *Mol. Neurodegener.* **16,** 4 (2021).
- 32. Pu, J. *et al.* Effects of pharmacological treatment on metabolomic alterations in animal models of depression. *Transl. Psychiatry* **12,** 175 (2022).
- 33. Murgia, F. *et al.* Metabolomic Changes in Patients Affected by Multiple Sclerosis and Treated with Fingolimod. *Metabolites* **13,** (2023).
- 34. Lawlor, D. A., Harbord, R. M., Sterne, J. A. C., Timpson, N. & Davey Smith, G. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. *Stat. Med.* **27,** 1133–1163 (2008).
- 35. Smith, G. D. & Ebrahim, S. "Mendelian randomization": can genetic epidemiology contribute to understanding environmental determinants of disease? *Int. J. Epidemiol.* **32,** 1–22 (2003).
- 36. Abdellaoui, A., Yengo, L., Verweij, K. J. H. & Visscher, P. M. 15 years of GWAS discovery: Realizing the promise. *Am. J. Hum. Genet.* **110,** 179–194 (2023).
- 37. Lord, J. *et al.* Disentangling independent and mediated causal relationships between blood metabolites, cognitive factors, and alzheimer's disease. *Biological Psychiatry Global Open Science* **2,** 167–179 (2022).
- 38. Zacharias, H. U. *et al.* A metabolome-wide association study in the general population reveals decreased levels of serum laurylcarnitine in people with depression. *Mol. Psychiatry* **26,** 7372–7383 (2021).
- 39. Davyson, E. *et al.* Metabolomic investigation of major depressive disorder identifies a potentially causal association with polyunsaturated fatty acids. *Biol. Psychiatry* **94,** 630–639 (2023).
- 40. Ge, A., Sun, Y., Kiker, T., Zhou, Y. & Ye, K. A metabolome-wide Mendelian randomization study prioritizes potential causal circulating metabolites for multiple sclerosis. *J. Neuroimmunol.* **379,** 578105 (2023).
- 41. Stacey, D., Benyamin, B., Lee, S. H. & Hyppönen, E. A Metabolome-Wide Mendelian Randomization Study Identifies Dysregulated Arachidonic Acid Synthesis as a Potential Causal Risk Factor for Bipolar Disorder. *Biol. Psychiatry* (2024). doi:10.1016/j.biopsych.2024.02.1005
- 42. Purves, K. L. *et al.* A major role for common genetic variation in anxiety disorders. *Mol. Psychiatry* **25,** 3292–3303 (2020).
- 43. Meier, S. M. *et al.* Genetic Variants Associated With Anxiety and Stress-Related Disorders: A Genome-Wide Association Study and Mouse-Model Study. *JAMA Psychiatry* (2019). doi:10.1001/jamapsychiatry.2019.1119
- 44. Kurki, M. I. *et al.* FinnGen provides genetic insights from a well-phenotyped isolated population. *Nature* **613,** 508–518 (2023).
- 45. Mullins, N. *et al.* Genome-wide association study of more than 40,000 bipolar disorder cases provides new insights into the underlying biology. *Nat. Genet.* **53,** 817–829 (2021).
- 46. Howard, D. M. *et al.* Genome-wide meta-analysis of depression identifies 102 independent variants and highlights the importance of the prefrontal brain regions. *Nat. Neurosci.* **22,** 343–352 (2019).
- 47. Levey, D. F. *et al.* Bi-ancestral depression GWAS in the Million Veteran Program and meta-analysis in >1.2 million individuals highlight new therapeutic directions. *Nat. Neurosci.* **24,** 954–963 (2021).
- 48. Trubetskoy, V. *et al.* Mapping genomic loci implicates genes and synaptic biology in schizophrenia. *Nature* **604,** 502–508 (2022).
- 49. van Rheenen, W. *et al.* Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology. *Nat. Genet.* **53,** 1636–1648 (2021).
- 50. International Multiple Sclerosis Genetics Consortium. Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. *Science* **365,** (2019).
- 51. Nalls, M. A. *et al.* Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. *Lancet Neurol.* **18,** 1091–1102 (2019).
- 52. Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of genomewide association scans. *Bioinformatics* **26,** 2190–2191 (2010).
- 53. Liu, H. *et al.* Mendelian randomization highlights significant difference and genetic heterogeneity in clinically diagnosed Alzheimer's disease GWAS and self-report proxy phenotype GWAX. *Alzheimers Res. Ther.* **14,** 17 (2022).
- 54. Lumsden, A. L., Mulugeta, A., Zhou, A. & Hyppönen, E. Apolipoprotein E (APOE) genotype-associated disease risks: a phenome-wide, registry-based, case-control study utilising the UK Biobank. *EBioMedicine* **59,** 102954 (2020).
- 55. Bulik-Sullivan, B. *et al.* LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. *Nat. Genet.* **47,** 291–295 (2015).
- 56. Grotzinger, A. D. *et al.* Genomic structural equation modelling provides insights into the multivariate genetic architecture of complex traits. *Nat. Hum. Behav.* **3,** 513–525 (2019).
- 57. Grotzinger, A. D., Fuente, J. de la, Privé, F., Nivard, M. G. & Tucker-Drob, E. M. Pervasive Downward Bias in Estimates of Liability-Scale Heritability in Genome-wide Association Study Meta-analysis: A Simple Solution. *Biol. Psychiatry* **93,** 29–36 (2023).
- 58. Chen, Y. *et al.* Genomic atlas of the plasma metabolome prioritizes metabolites implicated in human diseases. *Nat. Genet.* **55,** 44–53 (2023).
- 59. Hysi, P. G. *et al.* Metabolome Genome-Wide Association Study Identifies 74 Novel

 Genomic Regions Influencing Plasma Metabolites Levels. *Metabolites* **12,** (2022). 60. Murphy, A. E., Schilder, B. M. & Skene, N. G. MungeSumstats: A Bioconductor package for the standardisation and quality control of many GWAS summary statistics. *Bioinformatics* (2021). doi:10.1093/bioinformatics/btab665 61. Chang, C. C. *et al.* Second-generation PLINK: rising to the challenge of larger and richer datasets. *Gigascience* **4,** s13742–015–0047–8 (2015). 62. 1000 Genomes Project Consortium *et al.* A global reference for human genetic variation. *Nature* **526,** 68–74 (2015). 63. Elsworth, B. *et al.* The MRC IEU OpenGWAS data infrastructure. *BioRxiv* (2020). doi:10.1101/2020.08.10.244293 64. Palmos, A. B. *et al.* Proteome-wide Mendelian randomization identifies causal links between blood proteins and severe COVID-19. *PLoS Genet.* **18,** e1010042 (2022). 65. Bowden, J. *et al.* Assessing the suitability of summary data for two-sample Mendelian randomization analyses using MR-Egger regression: the role of the I2 statistic. *Int. J. Epidemiol.* **45,** 1961–1974 (2016). 66. Burgess, S. *et al.* Guidelines for performing Mendelian randomization investigations: update for summer 2023. *Wellcome Open Res.* **4,** 186 (2019). 67. Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. *Journal of the Royal Statistical Society: Series B (Methodological)* **57,** 289–300 (1995). 68. Bowden, J., Davey Smith, G., Haycock, P. C. & Burgess, S. Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator. *Genet. Epidemiol.* **40,** 304–314 (2016). 69. Burgess, S., Bowden, J., Dudbridge, F. & Thompson, S. G. Robust instrumental variable methods using multiple candidate instruments with application to Mendelian randomization. *arXiv* (2016). doi:10.48550/arxiv.1606.03729 70. Xue, H., Shen, X. & Pan, W. Constrained maximum likelihood-based Mendelian randomization robust to both correlated and uncorrelated pleiotropic effects. *Am. J. Hum. Genet.* **108,** 1251–1269 (2021). 71. Burgess, S., Foley, C. N., Allara, E., Staley, J. R. & Howson, J. M. M. A robust and efficient method for Mendelian randomization with hundreds of genetic variants. *Nat. Commun.* **11,** 376 (2020). 72. Rees, J. M. B., Wood, A. M., Dudbridge, F. & Burgess, S. Robust methods in Mendelian randomization via penalization of heterogeneous causal estimates. *PLoS One* **14,** e0222362 (2019). 73. Bowden, J., Davey Smith, G. & Burgess, S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. *Int. J. Epidemiol.* **44,** 512–525 (2015). 74. Zhu, Z. *et al.* Causal associations between risk factors and common diseases inferred from GWAS summary data. *Nat. Commun.* **9,** 224 (2018). 75. Yengo, L. *et al.* Meta-analysis of genome-wide association studies for height and body mass index in ∼700000 individuals of European ancestry. *Hum. Mol. Genet.* **27,** 3641– 3649 (2018). 76. Pulit, S. L. *et al.* Meta-analysis of genome-wide association studies for body fat distribution in 694 649 individuals of European ancestry. *Hum. Mol. Genet.* **28,** 166– 174 (2019). 77. Okbay, A. *et al.* Polygenic prediction of educational attainment within and between families from genome-wide association analyses in 3 million individuals. *Nat. Genet.* **54,** 437–449 (2022). 78. Zuber, V., Colijn, J. M., Klaver, C. & Burgess, S. Selecting likely causal risk factors

- from high-throughput experiments using multivariable Mendelian randomization. *Nat. Commun.* **11,** 29 (2020).
- 79. Lord, J. *et al.* Mendelian randomization identifies blood metabolites previously linked to midlife cognition as causal candidates in Alzheimer's disease. *Proc. Natl. Acad. Sci. USA* **118,** (2021).
- 80. Vilhjálmsson, B. J. *et al.* Modeling linkage disequilibrium increases accuracy of polygenic risk scores. *Am. J. Hum. Genet.* **97,** 576–592 (2015).
- 81. Choi, S. W., Mak, T. S.-H. & O'Reilly, P. F. Tutorial: a guide to performing polygenic risk score analyses. *Nat. Protoc.* **15,** 2759–2772 (2020).
- 82. Pain, O., Al-Chalabi, A. & Lewis, C. M. The genopred pipeline: A comprehensive and scalable pipeline for polygenic scoring. *medRxiv* (2024). doi:10.1101/2024.06.12.24308843
- 83. Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data. *Nature* **562,** 203–209 (2018).
- 84. Zhang, Q., Privé, F., Vilhjálmsson, B. & Speed, D. Improved genetic prediction of complex traits from individual-level data or summary statistics. *Nat. Commun.* **12,** 4192 (2021).
- 85. Ni, G. *et al.* A comparison of ten polygenic score methods for psychiatric disorders applied across multiple cohorts. *Biol. Psychiatry* **90,** 611–620 (2021).
- 86. Monti, R. *et al.* Evaluation of polygenic scoring methods in five biobanks shows larger variation between biobanks than methods and finds benefits of ensemble learning. *Am. J. Hum. Genet.* **111,** 1431–1447 (2024).
- 87. Manichaikul, A. *et al.* Robust relationship inference in genome-wide association studies. *Bioinformatics* **26,** 2867–2873 (2010).
- 88. Spargo, T. P. *et al.* Statistical examination of shared loci in neuropsychiatric diseases using genome-wide association study summary statistics. (2023). doi:10.7554/eLife.88768
- 89. Giambartolomei, C. *et al.* Bayesian test for colocalisation between pairs of genetic association studies using summary statistics. *PLoS Genet.* **10,** e1004383 (2014).
- 90. Võsa, U. *et al.* Large-scale cis- and trans-eQTL analyses identify thousands of genetic loci and polygenic scores that regulate blood gene expression. *Nat. Genet.* **53,** 1300– 1310 (2021).
- 91. Zhu, Z. *et al.* Integration of summary data from GWAS and eQTL studies predicts complex trait gene targets. *Nat. Genet.* **48,** 481–487 (2016).
- 92. Westra, H.-J. *et al.* Systematic identification of trans eQTLs as putative drivers of known disease associations. *Nat. Genet.* **45,** 1238–1243 (2013).
- 93. Lloyd-Jones, L. R. *et al.* The genetic architecture of gene expression in peripheral blood. *Am. J. Hum. Genet.* **100,** 228–237 (2017).
- 94. Auwerx, C. *et al.* Exploiting the mediating role of the metabolome to unravel transcript-to-phenotype associations. *Elife* **12,** (2023).
- 95. Yoshiji, S. *et al.* Proteome-wide Mendelian randomization implicates nephronectin as an actionable mediator of the effect of obesity on COVID-19 severity. *Nat. Metab.* **5,** 248–264 (2023).
- 96. Koletzko, B. *et al.* FADS1 and FADS2 polymorphisms modulate fatty acid metabolism and dietary impact on health. *Annu. Rev. Nutr.* **39,** 21–44 (2019).
- 97. Myers, T. A., Chanock, S. J. & Machiela, M. J. Ldlinkr: an R package for rapidly calculating linkage disequilibrium statistics in diverse populations. *Front. Genet.* **11,** 157 (2020).
- 98. Jansen, R. *et al.* The Metabolome-Wide Signature of Major Depressive Disorder. *Res. Sq.* (2023). doi:10.21203/rs.3.rs-3127544/v1
- 99. Zeng, L. *et al.* Causal effects of fatty acids on depression: Mendelian randomization study. *Front. Nutr.* **9,** 1010476 (2022).
- 100. Gao, Y. *et al.* Association between Arachidonic Acid and the Risk of Schizophrenia: A Cross-National Study and Mendelian Randomization Analysis. *Nutrients* **15,** (2023).
- 101. Whelan, J. & Fritsche, K. Linoleic acid. *Adv. Nutr.* **4,** 311–312 (2013).
- 102. Tallima, H. & El Ridi, R. Arachidonic acid: Physiological roles and potential health benefits - A review. *J. Advanc. Res.* **11,** 33–41 (2018).
- 103. Innes, J. K. & Calder, P. C. Omega-6 fatty acids and inflammation. *Prostaglandins Leukot Essent Fatty Acids* **132,** 41–48 (2018).
- 104. Yuan, N., Chen, Y., Xia, Y., Dai, J. & Liu, C. Inflammation-related biomarkers in major psychiatric disorders: a cross-disorder assessment of reproducibility and specificity in 43 meta-analyses. *Transl. Psychiatry* **9,** 233 (2019).
- 105. Perry, B. I. *et al.* Associations of immunological proteins/traits with schizophrenia, major depression and bipolar disorder: A bi-directional two-sample mendelian randomization study. *Brain Behav. Immun.* **97,** 176–185 (2021).
- 106. Wang, L., Luo, G., Zhang, L.-F. & Geng, H.-X. Neuroprotective effects of epoxyeicosatrienoic acids. *Prostaglandins Other Lipid Mediat* **138,** 9–14 (2018).
- 107. Su, K.-P. *et al.* Phospholipase A2 and cyclooxygenase 2 genes influence the risk of interferon-alpha-induced depression by regulating polyunsaturated fatty acids levels. *Biol. Psychiatry* **67,** 550–557 (2010).
- 108. Adams, C. D. Circulating glutamine and alzheimer's disease: A mendelian randomization study. *Clin Interv Aging* **15,** 185–193 (2020).
- 109. Chen, J. & Herrup, K. Glutamine acts as a neuroprotectant against DNA damage, beta-amyloid and H2O2-induced stress. *PLoS One* **7,** e33177 (2012).
- 110. Sims, J. R. *et al.* Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. *JAMA* **330,** 512–527 (2023).
- 111. Bernal-Vega, S., García-Juárez, M. & Camacho-Morales, A. Contribution of ceramides metabolism in psychiatric disorders. *J. Neurochem.* **164,** 708–724 (2023).
- 112. Zhuo, C. *et al.* Acid sphingomyelinase/ceramide system in schizophrenia: implications for therapeutic intervention as a potential novel target. *Transl. Psychiatry* **12,** 260 (2022).
- 113. Pekala, J. *et al.* L-carnitine--metabolic functions and meaning in humans life. *Curr Drug Metab* **12,** 667–678 (2011).
- 114. Beghi, E. *et al.* Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for ALS. *Amyotroph. Lateral Scler. Frontotemporal Degener.* **14,** 397–405 (2013).
- 115. Pennisi, M. *et al.* Acetyl-L-Carnitine in Dementia and Other Cognitive Disorders: A Critical Update. *Nutrients* **12,** (2020).
- 116. Gharighnia, S., Omidi, A., Ragerdi Kashani, I., Sepand, M. R. & Pour Beiranvand, S. Ameliorative effects of acetyl-L-carnitine on corpus callosum and functional recovery in demyelinated mouse model. *Int. J. Neurosci.* 1–11 (2022). 1067 doi:10.1080/00207454.2022.2107515
- 117. Sarraf, P. *et al.* The correlation of the serum level of L-carnitine with disease severity in patients with Amyotrophic lateral sclerosis. *J. Clin. Neurosci.* **89,** 232–236 (2021).
- 118. Harirchian, M. H., Babaie, S., Keshtkaran, N. & Bitarafan, S. The association of serum carnitine levels with severity of fatigue in patients with multiple sclerosis: A pilot study. *CJN* **22,** 30–34 (2023).
- 119. Custers, Emma, E. M., Kiliaan & Amanda, J. Dietary lipids from body to brain. *Prog. Lipid Res.* **85,** 101144 (2022).
- 120. Zahoor, I., Rui, B., Khan, J., Datta, I. & Giri, S. An emerging potential of metabolomics in multiple sclerosis: a comprehensive overview. *Cell Mol. Life Sci.* **78,** 3181–3203

(2021).

- 121. Zhang, Y., Guo, S., Xie, C. & Fang, J. Uridine metabolism and its role in glucose, lipid, and amino acid homeostasis. *Biomed Res. Int.* **2020,** 7091718 (2020).
- 122. Zhang, Y. *et al.* Plasma branched-chain and aromatic amino acids correlate with the gut microbiota and severity of Parkinson's disease. *npj Parkinsons Disease* **8,** 48 (2022).
- 123. Barichella, M. *et al.* Muscle-targeted nutritional support for rehabilitation in patients with parkinsonian syndrome. *Neurology* **93,** e485–e496 (2019).
- 124. Lewis, C. M. & Vassos, E. Polygenic risk scores: from research tools to clinical instruments. *Genome Med.* **12,** 44 (2020).
- 125. Albiñana, C. *et al.* Multi-PGS enhances polygenic prediction by combining 937 polygenic scores. *Nat. Commun.* **14,** 4702 (2023).
- 126. Yang, L. G., March, Z. M., Stephenson, R. A. & Narayan, P. S. Apolipoprotein E in lipid metabolism and neurodegenerative disease. *Trends Endocrinol. Metab.* **34,** 430– 445 (2023).